Posts Tagged ‘studies’
Controversial Studies Trigger Drop Off In Osteoporosis Treatment
Dr. Angelo Malamis says that 90 percent of his patients who have undergone a treatment called balloon kyphoplasty for vertebral fractures report significant reductions in pain and disability. But the number of kyphoplasty referrals Malamis has received from primary care doctors has dropped sharply since two controversial studies were published last year in the New England Journal of Medicine…
NanoViricides, Inc. To Present Anti-Influenza Drug Candidate FluCide™ Studies At The Influenza Congress 2009
NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), announced that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (http://www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment. Dr.
Automation Is No Substitute For Accuracy In Nerve Conduction Studies
To the patient, automated nerve conduction studies (NCSs) may sound appealing because they are less invasive than needle electromyography (EMG). To the physician with no formal electrodiagnostic (EDX) training, the ability to perform an automated test in their office is convenient for patients and may generate additional revenue for their practice.
Scientific Studies Confirm The Value Of Botulinum Toxin Type A (Botox) In Treating And Preventing Chronic Migraine
Four separate studies[i] representing the findings of clinical trials in the U.S., Canada and Europe have confirmed the value of onabotulinumtoxinA in treating and preventing chronic migraine in adults. These studies found that treatment with botulinum toxin type A was associated with significantly fewer headache days, less headache-related disability, and significantly improved quality of life.
Pharmacy 102: Drug Studies – Who What When Where and Why
 |
Almost every American takes a drug every day; many take three or more. This series presented by the UCSF Osher Lifelong Learning Institute explores your medicine, your health and your money. In this episode join John Flaherty, director of medical affairs at Gilead Science, Inc, as he explores the use of drug studies. Series: "UCSF Mini Medical School for the Public" [9/2007] [Health and Medicine] [Show ID: 13072]
|
From:uctelevision
Views:3717
  8ratings
|
| Time:01:29:31 | More inEducation |
Studies Confirm That Arch Chemicals’ Vantocil FHC Antimicrobial Product Is Effective Against Swine Flu Virus
Arch Chemicals, Inc. announced today that research has demonstrated that its Vantocil? FHC antimicrobial product, which has long been used in hygiene applications in Europe and other global regions, is also highly effective in controlling the causative agent of swine flu, Swine Influenza A (H1N1) virus.
Comparative Effectiveness Studies Raise Questions About Popular Back Pain Treatment
New studies on treating back pain from a fractured spine could call more attention to the type of comparative effectiveness research health policy experts and President Barack Obama have embraced in their quest to increase quality of care while lowering costs.
Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses In Animal Studies
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that the company’s SynCon? H1N1 influenza DNA vaccines achieved protection against current circulating swine origin influenza A/H1N1 viruses in animal studies.
Need For Studies On People With Weakened Immune Systems: Vulnerability To Flu And Response To Vaccination
An article published in the August edition of The Lancet Infectious Diseases reports that additional research is required on the vulnerability to the new H1N1 flu strain of different immunosuppressed populations. The possible effectiveness and side-effects of future vaccines also need to be evaluated.
PAION AG: Phase Ib And IIa Studies Of The Anesthetic/Sedative CNS 7056 On Track
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the respective Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that the Company should proceed as planned with their Phase IIa study as well as Phase Ib of CNS 7065, a new short-acting intravenous anesthetic/sedative.
Rx Drug Compare
Translator
By N2H